Clinical Trial Update: Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating uproleselan with cladribine and low-dose cytarabine in patients with treated secondary acute myeloid leukemia; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Cytarabine (Low-Dose) (cytarabine)
• Leustatin (cladribine)
• Uproleselan (uproleselan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Secondary Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-10-20